Some of our cancer centers are experiencing issues.  View More Important Notifications x
texas oncology more breakthroughs. more victories



Thomas Hutson, D.O., Pharm.D.

Thomas Hutson, D.O., Pharm.D.

Provider Type: Physician


General Summary

Dr. Hutson is the director of the Urologic Oncology Program and co-chair of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center in Dallas, as well as a Professor of Medicine at Texas A&M College of Medicine. Dr. Hutson received his bachelor’s and Doctor of Pharmacy degrees from Ohio Northern University, and his Doctor of Osteopathic Medicine degree from Ohio University. He completed residency in internal medicine, followed by fellowships in medical oncology and experimental therapeutics at the Cleveland Clinic.

Faith, and the relationship between religion and medicine, has been of particular importance to Dr. Hutson, especially in the area of end-of-life care. He has served as the medical director for Holy Savior Hospice in Dallas, and is an active member of the Christian Medical Dental Association. He has earned a Master of Biblical and Theological Studies degree from Dallas Theological Seminary and a Master of Divinity degree from The Southern Baptist Theological Seminary.

Research Interest

Dr. Hutson is recognized internationally as a leader in the field of urologic cancers, has authored over 500 scholarly works including original research, monographs and book chapters, is regularly invited to speak at medical venues around the world, and is the clinical lead investigator on several international research trials.

Other Information

Dr. Hutson is married to Kimberly Hodges Hutson and the couple reside in Plano with their two sons.


  • Current optimal chemotherapy for advanced urothelial cancer.

    Expert Review of Anticancer Therapy, 2008

  • A novel multitargeted tyrosine kinase inhibitor.

    Current Oncology Report, 2007

  • Management of recurrent testicular germ cell tumors.

    Oncologist, 2007

  • Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.

    Cancer, 2007

  • Novel agents for urothelial cancer: review

    British Journal of Urology International, 2007

Show all Publications
  • Phase I trial of PEG-Intron and rIL-2 in patients with metastatic renal cell carcinoma

    Cancer Chemotherapy and Pharmacology, 2007

  • Phase II trial of capecitabine and rHU-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy and moderate toxicity.

    Urology Oncology, 2007

  • Phase III randomized trial of sunitinib malate versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma.

    New England Journal of Medicine, 2007

  • Recent advances in the therapy of renal cancer.

    Expert Opinion on Biological Therapy, 2007

  • Renal Cell Carcinoma: Recent Advances.

    The Cancer Journal , 2007

  • Safety and tolerability of sorafenib in clear-cell renal cell carcinoma – a phase III overview.

    Expert Review of Anticavity Therapy, 2007

  • Targeted therapy for renal cell carcinoma: A new treatment paradigm

    Baylor Health Care Center Proceedings, 2007

  • The evolving role of novel targeted agents in renal cell carcinoma.

    Oncology, 2007

  • Treatment Approaches in Renal cancer Global Evaluation Trial (TARGETs)

    New England Journal of Medicine , 2007

  • A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma.

    Clinical Genitourinary Cancer, 2006

  • Phase I trial of phenoxodiol delivered by continuous intravenous infusion.

    Annals of Oncology, 2006

  • Problems with randomized discontinuation design.

    Journal of Clinical Oncology, 2006

  • Systemic Chemotherapy for Urothelial Cancer.

    Clinical Genitourinary Cancer, 2006

  • Treatment of Patients with Metastatic Renal Cell Carcinoma: A RAND appropriateness panel

    Cancer, 2006